<DOC>
	<DOCNO>NCT01758471</DOCNO>
	<brief_summary>This study aim investigate effect acarbose intestinal microbiome incretins , therefore explore new pathway new target treat type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Acarbose Intestinal Microbiome Incretins Type 2 Diabetes</brief_title>
	<detailed_description>In recent year , Endocrinologist Diabetologists find intestine might serve novel target treat diabetes metabolic disease . Incretins well-known hormone secrete intestine , CCK（Cholecystokinin ) , Serotonin , GIP ( gastric inhibitory polypeptide ) GLP-1 ( glucagon like peptide 1 ) , help control wholesome metabolic status effect pancreatic islet cell , hypothalamus neuron gastrointestinal movement . Gut microbiome recently reveal exert major effect host 's immune system metabolic balance various metabolite component . α-glucosidase inhibitor use anti-diabetes medicine dozen year . They know effective delaying glucose absorption small intestine . Questions arisen delay glucose absorption change intestinal bacteria flora component increase bacteria fed glucose , influence incretin secretion , since glucose sensitive L cell ( secrete GLP-1 ) locate distal part small intestine colon , hypoglycemia effect α-glucosidase inhibitor might mediate either intestinal flora incretins . To address question find new target intestine treat diabetes , therefore design study , take advantage clinical trial basic biomedical study find α-glucosidase inhibitor- Acarbose ( Bayer , Corp. ) could change profile intestinal incretins microbiome . Study design : 1 . Multi-center , open label , randomize , positive control cohort . 2 . 110 case newly-diagnosed Type-2 Diabetes patient five clinic center Shanghai , China Mainland . 3 . All patient sign consent screen criterion enrol study . 4 . 55 case Type 2 Diabetes assign glucobay treatment another 55 take glipizide . 5 . 50 healthy volunteer baseline data comparison . 6 . The duration whole study 3 month . 1 . Before treatment , patient require OGTT ( oral glucose tolerant test ) IRT ( insulin release test ) test give feces . Standard meal require one day feces collect . 2 . In 3 month , patient take medicine glucose monitor closely visit outpatient office month . 3 . In end study , patient require receive OGTT IRT give feces . 7 . Serum feces store -80℃ biomarkers investigation microbiome sequencing . 8 . After 3 month intervention , patient observe another 3 month access routine clinic visiting .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Newly diagnose Type 2 Diabetes , without previous drug treatment , 7.0 mmol/l &lt; =FBG &lt; =13.O mmol/l , HbA1C &lt; =10 % Body mass index ( BMI ) &lt; 35kg/m2 ( inclusive ) ; Understand voluntarily sign informed consent document prior study related assessments/procedures conduct Having good study compliance Intestinal surgery recent abdominal surgery within 1 year Taken immunosuppressive agent , steroid , antidiarrhea agent , antibiotic gastrointestinal motility agent within 3 month Severe liver dysfunction , include serum alanine aminotransferase concentration 2.5 time upper limit normal range , abnormal renal function ( GFR &lt; 60ml/min ) Other severe condition put patient high risk study Any clinically significant allergic disease Women pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>gut microbiome</keyword>
	<keyword>incretin</keyword>
	<keyword>Sulfonylurea</keyword>
	<keyword>α-glucosidase inhibitor</keyword>
</DOC>